ampreloxetine
ampreloxetine: developed by 1 company · 1 clinical trial tracked.
ampreloxetine evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect ampreloxetine to TBPH; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could ampreloxetine → TBPH affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Symptomatic Neurogenic Orthostatic Hypotension
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Theravance Biopharma, Inc. (TBPH) Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 |
Clinical Trials (1)
A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants With Multiple System Atrophy
Primary endpoint: Change in OHSA composite score at Week 8 during the double-blind RW period
InterventionalRandomizedquadruple102 targetStarted 2023-06Completion 2028-0150 sites · Argentina, Australia, Austria, Brazil…Theravance Biopharma
Frequently asked questions
Who is developing ampreloxetine?
ampreloxetine is being developed by Theravance Biopharma, Inc..
How many clinical trials involve ampreloxetine?
BioSniper tracks 1 clinical trial involving ampreloxetine.